At a Glance
| PMB/CDL status | Yes — CDL 010. All registered medical schemes must cover diagnosis, treatment, and care. |
| Typical annual cost | R3,700 (mild, metformin only) to R60,000+ (severe, insulin + newer agents) |
| GLP-1 escalation risk | Yes — semaglutide (Ozempic) now increasingly prescribed; NOT covered by standard CDL formulary |
| Gap cover relevant | Yes — for cardiovascular complications (cardiac events, stroke), diabetic foot admissions |
| Managed care required | Most schemes require CDE (Chronic Disease Enrolment) registration to access full benefits |
What Is Type 2 Diabetes?
Type 2 diabetes mellitus (T2DM) is a chronic metabolic condition in which the body either produces insufficient insulin or becomes resistant to its effects, resulting in elevated blood glucose levels. Unlike type 1 diabetes — which is autoimmune and insulin-dependent from diagnosis — type 2 typically develops gradually, often over years.
South Africa has one of the highest diabetes burdens in sub-Saharan Africa. An estimated 12–15% of adults aged 25 and older are living with T2DM — approximately 4.5 million people — with a significant proportion undiagnosed. The condition is closely linked to obesity, urbanisation, and sedentary lifestyle, all of which are rising trends in South Africa.
Sources: Mthembu et al. (2021) systematic review & meta-analysis, IJERPH; SADHS 2016.
Medical Aid Coverage: The Short Version
Good news: type 2 diabetes is on the Chronic Disease List (CDL). Under CMS Regulation 15H, every registered medical scheme in South Africa must fully fund the diagnosis, treatment, and care of T2DM at Prescribed Minimum Benefit (PMB) level. No scheme can refuse to cover your diabetes medication as a chronic condition.
The PMB algorithm specifies what must be funded:
- First line: Generic metformin + lifestyle modification
- Second line: Add a sulphonylurea (generic gliclazide MR)
- If oral agents fail: Add insulin (NPH isophane insulin at minimum)
The catch: The CDL formulary is conservative. Newer medications — SGLT-2 inhibitors (empagliflozin/Jardiance), DPP-4 inhibitors (sitagliptin/Januvia), and GLP-1 receptor agonists (semaglutide/Ozempic) — are not in the standard PMB algorithm. Some schemes fund these via managed care protocols or Chronic Disease Enrolment (CDE) programmes. Many don't. This is where plan selection matters.
Source: CMS CMScript 9 of 2022; CMS PMB Regulations.
Treatment Pathways and What They Cost
First-Line: Metformin + Lifestyle
Most people with T2DM start on metformin and are advised to modify their diet and increase physical activity. Metformin is one of the oldest, safest, and cheapest diabetes medications — and diabetes is on the Chronic Disease List, so every scheme must pay for it on its formulary.
| Medication | Dose | Estimated monthly cost (2026) | CDL-funded? |
|---|---|---|---|
| Metformin 850mg (generic) | 850mg twice daily | ~R80 | Yes |
Annual cost (mild, well-controlled): approximately R3,700 — including medication, 3 GP visits, 2 HbA1c tests, and basic blood work.
Note: Medication costs are estimates pending SAHPRA Single Exit Price (SEP) verification.
Second-Line: Add a Second Agent
When metformin alone doesn't achieve glucose targets, SA guidelines (SEMDSA 2024) recommend adding a second agent. Choice depends on cardiovascular risk, cost, and individual patient factors.
| Medication | Class | Estimated monthly cost | CDL-funded? |
|---|---|---|---|
| Gliclazide MR 30mg (generic) | Sulphonylurea | ~R120 | Yes (in PMB algorithm) |
| Empagliflozin 10mg (Jardiance) | SGLT-2 inhibitor | ~R1,100 | Scheme-dependent — NOT in PMB algorithm |
| Sitagliptin 100mg (Januvia) | DPP-4 inhibitor | ~R820 | Scheme-dependent — NOT in PMB algorithm |
SEMDSA 2024 increasingly recommends empagliflozin for patients with cardiovascular risk because it reduces cardiac mortality (EMPA-REG OUTCOME trial). However, at R1,100/month, it adds R13,200/year in costs that not all schemes cover. This is one of the most significant out-of-pocket risks for South Africans with T2DM.
Annual cost (moderate, dual therapy): R7,560 (metformin + gliclazide) to R19,360 (metformin + empagliflozin).
Third-Line: GLP-1 Agonists and Insulin
The most complex (and most expensive) treatment stage involves injectable agents.
| Medication | Estimated monthly cost | CDL-funded? |
|---|---|---|
| Semaglutide 1mg (Ozempic, originator) | ~R2,900 | No — NOT in PMB formulary |
| Semaglutide (generic, 2026) | ~R230–R500 | No — very new, limited availability |
| Insulin NPH (generic) | ~R220 | Yes — funded under PMB |
| Insulin glargine (Lantus/generic) | ~R950 | Scheme-dependent |
Ozempic (semaglutide) has become increasingly prescribed for T2DM, particularly where weight management is a factor. The originator costs R2,900/month — R34,800/year. This is not covered by CDL benefit on most schemes and is typically an out-of-pocket cost unless the patient's scheme funds it via a managed care programme. Generic GLP-1 options began entering the SA market in early 2026 and may reduce this cost significantly over time.
Annual cost (severe, insulin or GLP-1 dependent): R28,600 to R60,760.
Source: Spotlight NSP (February 2026); News24 (March 2026); Basu et al., Value in Health Regional Issues (2022).
Regular Monitoring: What It Costs and What Your Medical Aid Covers
T2DM requires ongoing monitoring, regardless of severity. Minimum monitoring under CDL:
- HbA1c (blood glucose control indicator): at least 2× per year (~R220 each)
- Creatinine/eGFR (kidney function): annual (~R120)
- Lipid profile (cardiovascular risk): annual (~R180)
- Urine microalbumin (early kidney damage): annual (~R150)
- Annual foot assessment and eye examination (retinopathy screening)
Most of these are funded under your scheme's CDL benefit or pathology benefit. Continuous glucose monitors (CGM) — like the FreeStyle Libre or Dexcom G7 — are not PMB-funded and are typically an out-of-pocket expense unless your scheme's day-to-day benefit covers them.
Gap Cover for Type 2 Diabetes: Is It Worth It?
This is a question AURA gets often. The answer is nuanced.
Routine T2DM management — medication, blood tests, GP visits — is not a gap cover question. It's day-to-day and chronic benefit. Gap cover doesn't apply.
The risk that gap cover addresses is what T2DM does to your body over time. People with T2DM have 2–3× the risk of a cardiac event compared to the general population. A heart attack admission at a private hospital can cost R150,000–R300,000. Specialists (cardiologists, vascular surgeons) routinely charge 300–500% of the medical aid scheme rate. Gap cover closes that shortfall.
| Scenario | Estimated cost | Gap cover relevant? |
|---|---|---|
| Routine T2DM management (annual) | R3,700–R19,360 | No |
| Hyperglycaemic crisis (hospital) | ~R28,000 | Yes |
| Heart attack or stroke (hospital) | R150,000–R300,000 | Yes — critically |
| Diabetic foot amputation | R30,000–R100,000 | Yes |
Bottom line: At mild severity, gap cover is not driven by the diabetes itself — it's driven by your cardiovascular risk profile. At moderate to severe T2DM, especially with cardiovascular risk factors, gap cover becomes a priority.
Check Your Cover
Not sure if your medical aid covers your diabetes medication — or what it would cost if you had a cardiac event? AURA can check your specific plan against your conditions in under 10 minutes.
Based on 2026 South African medical aid data, SAHPRA pricing estimates, and CMS PMB regulations. Medication costs are estimates — consult your pharmacist or scheme formulary for current prices. This article provides information only and is not medical or financial advice.
Sources: Mthembu et al. (2021), IJERPH; CMS CMScript 9 of 2022; SEMDSA Diabetes Guidelines (2017, updated 2024); Spotlight NSP (2026); News24 (March 2026); Basu et al. Value in Health Regional Issues (2022).